Basic Information
| LncRNA/CircRNA Name | NCK1-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot |
| Sample | glioma tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | NCK1-AS1 expression was increased in regular and recurrent glioma tissues and TMZ-resistant cells.NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway. |
| Pubmed ID | 31750728 |
| Year | 2020 |
| Title | NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/TRIM24 |
External Links
| Links for NCK1-AS1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |